Look at a major AI-driven drug discovery collaboration aiming at neuroimmune disorders and implications for CNS development pipelines.
Key Takeaways
- Partnership is valued at more than $2.5 billion in potential payments
- Insilico reports AI reduces early-stage discovery timelines to about 12 to 18 months
- SK Biopharma will lead clinical development and commercialization for CNS-targeted programs